(Reuters) – Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn’s disease, a type of chronic inflammatory bowel disease.
(Reporting by Mariam Sunny in Bengaluru; Editing by Alan Barona)